Clinical Trial

Hepatitis B Vaccine Delivered Trans-dermally by MAP

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2025 (before its estimated August 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is Phase I, randomized, open-label, active-controlled study to evaluate the safety, tolerability, and immunogenicity of a hepatitis B vaccine administered trans-dermally via microneedle array patch (MAP) compared to the intra-muscular (IM) hepatitis B vaccine (Euvax B™), administered at Day (D) 0, Week (W) 4, W26 among healthy adults aged 19 to 40 years in the Republic of Korea.
Trial Details
NCT Number NCT06800131
Lead Sponsor International Vaccine Institute
Collaborators: QuadMedicine
Conditions Hepatitis B Vaccine
Enrollment 40 participants
Start Date 2025-02-05
Primary Completion 2026-08-05 (estimated)
Study Completion 2026-11-05 (estimated)
Updated on ClinicalTrials.gov 2025-01-29